NRTN

NRTN (neurturin) is a secreted neurotrophic factor of the GDNF family that signals through GPI-anchored co-receptors GFRα2 (preferred) and GFRα1 to activate the RET receptor tyrosine kinase, promoting survival and function of dopaminergic, parasympathetic, sensory, and enteric neurons (PMID:10861794, PMID:11003834, PMID:33444816). In the enteric nervous system, NRTN acutely regulates the activity of myenteric neuron subpopulations and smooth muscle contraction in a manner distinct from GDNF, determined by differential GFRα2 versus GFRα1 expression (PMID:33444816). Beyond classical neurotrophic roles, NRTN maintains HSV1 latency in adult sensory trigeminal neurons through GFRα2-expressing cells (PMID:28178213), promotes osteoblast differentiation downstream of sympathetic cholinergic signaling (PMID:40474233), and participates in macrophage alternative activation as a transcriptional target repressed by BHLHE40 (PMID:40467844).

1. 2000 High

   Establishing that NRTN signals through both GFRα2 (preferred) and GFRα1 to activate RET resolved how GDNF-family ligands exhibit receptor cross-talk and defined the core signaling mechanism for neurturin.

   Evidence Genetic deletion and biochemical manipulation of GFRα1/GFRα2 in primary midbrain dopaminergic and parasympathetic neuron cultures; receptor co-expression profiling in medullary thyroid carcinoma

   PMID:10822229 PMID:10861794

   Open questions at the time

   • No crystal structure of the NRTN–GFRα2–RET ternary complex
   • Relative contribution of GFRα1- vs GFRα2-mediated signaling in each neuronal subtype not quantified in vivo
2. 2000 High

   Demonstrating that NRTN supports distinct postnatal DRG sensory neuron subpopulations — and that this dependency is absent embryonically — established a developmental switch in trophic factor requirements for sensory neurons.

   Evidence In vitro survival assays of embryonic and postnatal DRG neurons with receptor expression profiling

   PMID:11003834

   Open questions at the time

   • In vivo validation of the postnatal survival switch using conditional NRTN knockouts not performed
   • Molecular mechanism governing the timing of trophic factor switch unknown
3. 2010 Medium

   Showing that NRTN persists longer than GDNF in brain tissue and produces sustained dopamine turnover after a single infusion provided a pharmacokinetic rationale for NRTN as a therapeutic neurotrophic agent.

   Evidence Convection-enhanced delivery of NRTN vs GDNF into rat striatum with ELISA, HPLC, and immunohistochemistry

   PMID:20153340

   Open questions at the time

   • Mechanism of NRTN precipitation at neutral pH not structurally resolved
   • Long-term (>2 week) persistence and safety not assessed
4. 2011 High

   AAV2-delivered NRTN to the substantia nigra provided dose-dependent neuroprotection of dopaminergic neurons and revealed that weight-loss toxicity arose from mistargeted diencephalic expression rather than nigral neurotrophic action, refining delivery strategy for Parkinson's disease gene therapy.

   Evidence Stereotaxic AAV2-NRTN injection in rats with 6-OHDA lesion model; dose escalation with ELISA, immunohistochemistry, and behavioral readouts; substantia nigra vs striatum targeting comparison

   PMID:21704161 PMID:23631873

   Open questions at the time

   • Downstream intracellular signaling cascades in protected neurons only partially characterized
   • Translation to non-human primate or clinical setting not addressed in these studies
5. 2017 Medium

   NRTN deprivation triggered HSV1 reactivation specifically in adult sensory trigeminal neurons expressing GFRα2, revealing an unexpected non-developmental role for NRTN in maintaining viral latency.

   Evidence Primary adult sensory neuron cultures with neurotrophic factor deprivation and latency/reactivation assays; GFRα2 expression correlation

   PMID:28178213

   Open questions at the time

   • In vivo confirmation of NRTN-dependent HSV1 latency maintenance not performed
   • Whether RET activation is required downstream of GFRα2 for latency maintenance unknown
6. 2021 High

   Calcium imaging combined with single-cell transcriptomics demonstrated that NRTN and GDNF acutely regulate distinct myenteric neuron subpopulations based on differential GFRα2/GFRα1 expression, establishing functional specialization of GDNF-family ligands in gut motility.

   Evidence Calcium imaging, single-cell/nucleus RNA-seq, and immunohistochemistry in mouse and human colon myenteric plexus

   PMID:33444816

   Open questions at the time

   • Downstream signaling pathways in enteric neuron subtypes not delineated
   • Consequences of NRTN loss specifically on GI motility in vivo not tested
7. 2023 Medium

   Co-immunoprecipitation identified TANGO1 (MIA3) as a physical interactor of NRTN in hepatocellular carcinoma cells, with both proteins promoting proliferation and EMT via PI3K/AKT/mTOR, extending NRTN signaling to a cancer context.

   Evidence Endogenous Co-IP, confocal microscopy, RNA-seq, and knockdown with proliferation/apoptosis/EMT readouts in HCC cell lines

   PMID:37211171

   Open questions at the time

   • Reciprocal Co-IP and mapping of NRTN–TANGO1 binding interface not reported
   • Whether this interaction is RET-dependent or represents a non-canonical pathway is unknown
   • Single cell-line system without in vivo validation
8. 2025 Medium

   ChIP-qPCR and epistasis experiments showed BHLHE40 directly represses Nrtn transcription in macrophages, placing NRTN downstream of BHLHE40 in alternative macrophage activation and asthma pathology — the first described transcriptional regulator of NRTN.

   Evidence Dual luciferase and ChIP-qPCR for promoter binding; in vivo OVA asthma model with Bhlhe40/Nrtn double knockdown; macrophage polarization assays

   PMID:40467844

   Open questions at the time

   • Whether NRTN acts in an autocrine or paracrine fashion on macrophages not resolved
   • Receptor and downstream pathway mediating NRTN's role in macrophage polarization not identified
9. 2025 Medium

   NRTN was shown to promote osteoblast differentiation from bone marrow mesenchymal stem cells and to rescue bone loss in OVX mice, linking sympathetic cholinergic nerve-derived NRTN to bone homeostasis.

   Evidence OVX mouse model with micro-CT, histomorphometry, osteoblast differentiation assays, ELISA, and Western blot

   PMID:40474233

   Open questions at the time

   • Receptor complex mediating NRTN's osteogenic effect (GFRα2/RET vs alternative) not identified
   • Whether NRTN acts directly on MSCs or through intermediate cell types not distinguished

• The structural basis of NRTN–GFRα2–RET complex assembly, the intracellular signaling cascades specific to NRTN (as distinct from GDNF), and the mechanisms underlying NRTN's non-neuronal functions in macrophage polarization and bone homeostasis remain unresolved.
• No atomic-resolution structure of the NRTN–GFRα2–RET complex
• NRTN-specific intracellular signaling branches not distinguished from generic RET signaling
• Transcriptional regulation of NRTN beyond BHLHE40 and LRRK2/Hedgehog axis is largely unknown